[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-395436-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-395436-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cervical-screening-pathway-routine-cervical-screening-ages-25-69-years","Cervical Screening Pathway - Routine Cervical Screening (Ages 25-69 Years)","","Clinical pathway flowcharts for routine cervical screening and follow-up management based on HPV testing with partial genotyping and liquid-based cytology (LBC) results. The content outlines decision points for HPV detected vs not detected, unsatisfactory test outcomes, and recommended intervals for repeat testing, including referral to colposcopic assessment. It also covers management transitions across pregnancy, immune-deficient participants, post-hysterectomy screening, and investigation of abnormal vaginal bleeding, with definitions for LSIL/HSIL and possible variants.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cervical-screening-pathway-routine-cervical-screening-ages-25-69-years/395436/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cervical-screening-pathway-routine-cervical-screening-ages-25-69-years/395436.png","ImageObject",300,407,{"name":42,"@type":43},"RuangKosong","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-26",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the next steps after a routine HPV test with partial genotyping when HPV is not detected?","Question",{"text":63,"@type":64},"The flowchart directs participants to return to routine 5-yearly screening using LBC, with timing based on program recommendations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the pathway handle unsatisfactory HPV or LBC results?",{"text":68,"@type":64},"Unsatisfactory results trigger repeat testing as soon as practical, ideally within 6 weeks, followed by the appropriate cytology and referral steps.",{"name":70,"@type":61,"acceptedAnswer":71},"When is direct referral to colposcopy recommended?",{"text":72,"@type":64},"Direct referral is recommended for screening participants who meet specific higher-risk criteria, including age 50+ and Aboriginal and/or Torres Strait Islander status, or being overdue by at least 2 years at initial screen.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},395436,1790489243,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Table of Contents-Flowcharts  \n6. 1: Routine Cervical Screening (ages 25-69 years) 2  \n6.2: Cervical Screening Pathway (Clinician collected or self-collected) 3  \n6.3: Cervical Screning Pathway (Clinician collected or self-collected) 4  \n6.4: Cervical Screening Pathway (Clinician collected or self-collected) 5  \n7.1: Management of a LBC prediction of HSIL in Pregnancy 6  \n7.2: Management of screen detected abnormalities in immune deficient screening participants 7  \n7.3: Screening after hysterectomy 8  \n8.1: Colposcopy management after LBC prediction of HSIL 9  \n8.2: Colposcopy management after LBC prediction of possible HSIL  10  \n8.3: Colposcopy management after LBC prediction of negative, pLSIL or LSIL 11  \n8.4: Colposcopy management after LBC prediction of atypical glandular/endocervical cells of undetermined significance 12  \n8.5: Management of LBC prediction of a high grade glandular lesion (AIS) 13  \n8.6: Management of LBC prediction of a possible high grade glandular lesion 14  \n8.7: Colposcopy management when LBC result is not available 15  \n9.1: Test of cure following treatment for high-grade squamous abnormalities 16  \n9.2: Follow up after excisional treatment for AIS 17  \n10.1: Investigation of people with abnormal vaginal bleeding 18  \n􀀗􀀏􀀒􀀛 ROUTINE CERVICAL SCREENING (AGES 25-69 YEARS)  \nHPV test with partial genotyping (ages 25-69)  \nHPV not detected  \nHPV  \ndetected  \nHPV  \ndetected  \nUnsatisfactory HPV test  \n(not 16/18)  \n(16/18)  \nRoutine 5-yearly  \n  LBC (reflex or collect cervical sample if self-collection was used)    \nLBC (reflex or collect at colposcopy)   \nRepeat as soon as practical, ideally within  \nscreening  \nUnsatisfactory LBC  \nNegative  \npLSIL/LSIL  \nLBC pHSIL or worse*  \nAny LBC result or unsatisfactory  \n6 weeks  \nHPV detected (16/18)  \nRoutine 5-yearly screening  \nRepeat as soon as practical, ideally within  \n6 weeks  \nLBC (reflex or collect at colposcopy)  \nHPV detected (not 16/18)  \nHPV not detected  \nDirect referral to colposcopy is recommended for screening participants who are:  \n• aged 50+ years  \n• Aboriginal and/or Torres Strait Islander  \n• overdue for screening by at least  \n2 years at initial screen  \nLBC (reflex or collect cervical sample if self-collection was used)  \nLEGEND  \n Test result  \n| | Recommendation |\n| --- | --- |\n| Woman’s risk of developing cervical cancer prLJ\\YZVYZ ^P[OPU [OL UL_[ Ä]L `LHYZ |  |\n|  Low |  |\n| | Intermediate |\n|  Higher |  |\n\nRefer for colposcopic assessment  \nHPV detected  \nany  \nLBC (reflex or collect at colposcopy)  \nHPV not detected  \nDES: diethylstilboestrol  \nLSIL: low-grade squamous intraepithelial lesion HSIL: high-grade squamous intraepithelial lesion  \npLSIL: possible low-grade squamousintraepithelial lesion  \npHSIL: possible high-grade squamousintraepithelial lesion  \n*Includes pHSIL, HSIL, cancer or glandular abnormality.  \nSuggested citation: Cancer Council Australia Cervical Cancer Screening Working Party. Clinical pathway: Cervical screening pathway. National Cervical Screening Program: Guidelines for the management of screen detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. CCA 2016. Accessible from [http://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening](http://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening). Updated Dec 2020.  \n2  \n􀀗􀀏􀀓􀀛 CERVICAL SCREENING PATHWAY (CLINICIAN COLLECTED OR SELF-COLLECTED)  \nHPV test with partial genotyping  \nHPV not detected  \nRoutine 5-yearly screening  \n|  Test result |\n| --- |\n|  Recommendation |\n|  |\n| \u003Cbr>Woman’s risk of developing cervical cancer |\n| SUHFXUVRUV ZLWKLQ WKH QH[W ðYH \\HDUV |\n|  Low |\n|  Intermediate |\n|  Higher |\n\nLEGEND  \nDES: diethylstilboestrol  \nLSIL: low-grade squamous intraepithelial lesion HSIL: high-grade squamous intraepithelial lesion  \npLSIL: possible low-grade squamousintraepithelial lesion  \npHSIL: possible high-grade squamousintraepithelial lesion  \n*Includes pHSIL, HSIL, cancer or gl","cbCaiscoVawBnsol","https://ap.wps.com/l/cbCaiscoVawBnsol","pdf",692936,18,"English","# Routine Cervical Screening (Ages 25-69 Years)\n## Cervical Screening Pathway (Clinician collected or self-collected)\n## Management of LBC prediction of HSIL in Pregnancy\n## Colposcopy management after LBC prediction of HSIL\n## Screening after hysterectomy\n## Investigation of people with abnormal vaginal bleeding","[{\"question\":\"What are the next steps after a routine HPV test with partial genotyping when HPV is not detected?\",\"answer\":\"The flowchart directs participants to return to routine 5-yearly screening using LBC, with timing based on program recommendations.\"},{\"question\":\"How does the pathway handle unsatisfactory HPV or LBC results?\",\"answer\":\"Unsatisfactory results trigger repeat testing as soon as practical, ideally within 6 weeks, followed by the appropriate cytology and referral steps.\"},{\"question\":\"When is direct referral to colposcopy recommended?\",\"answer\":\"Direct referral is recommended for screening participants who meet specific higher-risk criteria, including age 50+ and Aboriginal and/or Torres Strait Islander status, or being overdue by at least 2 years at initial screen.\"}]","Cervical Screening Pathway - Routine Cervical Screening (Ages 25-69 Years) | PDF",1790419544,45]